Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022
April 18 2022 - 3:47PM
Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced its speaker presentation
for the World Vaccine Congress Washington 2022, which is being held
in Washington, DC. on April 18-21, 2022. The company will be
showcasing its automated benchtop workstation – the BioXp™ system
and it’s automated solutions for accelerating vaccine discovery
workflows at booth #202.
The need for rapid vaccine development in response to emerging
pathogens has become increasingly clear during the COVID-19
pandemic. However, traditional vaccine discovery, development, and
production methods can be complicated for manufacturers,
regulators, and public health officials, especially for endemic
viruses that require adjustments to counter ongoing antigenic
variation. Codex DNA’s automated solution currently supports rapid
DNA and mRNA synthesis from digital sequence in a single automated
run. The BioXp 3250 system enables customers to synthesize
high-quality DNA and biologically active mRNA within 24 hours,
reducing turnaround time from weeks to days, increasing throughput
and scale, enhancing quality, and giving researchers complete
workflow control. Codex DNA also expects it’s proprietary Short
Oligonucleotide Ligation Assembly (SOLA) Enzymatic DNA Synthesis
(EDS) approach will further enable on-demand synthesis of DNA, mRNA
and protein and shorten the timeline for discovery and development
of mRNA-based vaccines, diagnostics, therapeutics, and personalized
medicines.
Codex DNA and RNAimmune have been working together to optimize
the development and validation of Codex DNA’s future mRNA synthesis
kits. In this effort, the two companies will also address the
integration of RNAimmune’s proprietary mRNA delivery solutions into
Codex DNA’s automated workflows to further streamline the vaccine
discovery process.
“We are excited to work with Codex DNA to accelerate
breakthroughs using mRNA platforms. Together, we can incorporate
our proprietary carrier molecules into Codex DNA’s mRNA synthesis
kits to improve automated production toward truly
transfection-ready mRNA with enhanced uptake and expression,” said
Dong Shen, Ph.D, CEO of RNAimmune. RNAimmune will showcase the
design and development of their novel Pan-Ras mRNA vaccine for
cancer therapy at the conference and also highlight the use of the
BioXp™ system in accelerating their discovery workflows.
FEATURED CUSTOMER
PRESENTATION: Targeting
KRAS mutations in cancer: new mRNA vaccine on the
horizonTrack: Cancer and
ImmunotherapyPresenter: Dong Shen, MD, PhD,
President & CEO, RNAimmuneDate/Time:
Wednesday, April 20, 3:40 pm Location: M4, Liberty
Salon I-K
“Together with RNAimmune, we are empowering our customers to
design, develop, and produce safe, high-quality vaccines faster
than ever before,” said Todd R. Nelson, PhD, CEO of Codex DNA. “I’m
excited for conference attendees to hear directly from Dr. Shen
about the impressive work being done in mRNA vaccines. Our
sustainable, scalable, and cost-effective approach has the
potential to completely transform how the world responds to
emerging viral threats in the future.”
Codex DNA currently offers a catalog of synthetic genomes,
including SARS-CoV-2, for research use for monoclonal antibody
treatments, small-molecule therapies, diagnostic assays, and new
vaccines against specific variants. For more information, please
visit the following link.About Codex DNACodex DNA
is empowering scientists with the ability to create novel,
synthetic biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp™ system consolidates, automates
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Codex DNA is a public company
based in San Diego. For more information, visit codexdna.com.
Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are
trademarks of Codex DNA Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements regarding Codex DNA’s progress made on achieving
corporate goals and the future release of products and services.
Such statements are based on current assumptions that involve risks
and uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond Codex DNA’s control, include risks described in Codex DNA’s
public filings, specifically the section entitled Risk Factors and
elsewhere in its annual Report on Form 10-K, which is anticipated
to be filed with the Securities and Exchange Commission on March
23, 2022. These forward-looking statements speak only as of the
date hereof and should not be unduly relied upon. Codex DNA
disclaims any obligation to update these forward-looking
statements.
Media Contact Richard D. LepkeDirector,
Investor Relationsir@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024